Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review.

IF 4.8 2区 医学 Q1 NEUROSCIENCES
Mario Santorelli, Andrea Miuli, Mauro Pettorruso, Francesco Di Carlo, Domenico De Berardis, Stefano L Sensi, Giovanni Martinotti, Massimo Clerici, Massimo di Giannantonio
{"title":"Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review.","authors":"Mario Santorelli, Andrea Miuli, Mauro Pettorruso, Francesco Di Carlo, Domenico De Berardis, Stefano L Sensi, Giovanni Martinotti, Massimo Clerici, Massimo di Giannantonio","doi":"10.2174/1570159X23666241023115252","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Co-occurrence of substance use disorders is frequent in patients with mental health disorders is a condition known as \"dual diagnosis\". The use of substances worsens the prognosis and lowers the quality of life of psychiatric patients. It also increases the risk of hospitalization and suicide rate.</p><p><strong>Objectives: </strong>To assess the effects of aripiprazole therapy on substance use and other psychiatric outcomes in dually diagnosed patients.</p><p><strong>Methods: </strong>We performed a systematic review conducted on 3 databases PUBMED, SCOPUS, and Web of Science, selecting original studies and analyzing the impact of aripiprazole therapy on dually diagnosed patients. Six hundred and fifty-five articles were founded and, after removing duplicates (n = 274) and applying the exclusion criteria, 12 articles were included in our systematic review.</p><p><strong>Results: </strong>12 studies were included, among which 6 were Randomized Controlled Trials. The Most frequent psychiatric diagnosis were schizoaffective disorders, schizophrenia, and bipolar disorders. Alcohol and cocaine use disorders were the most used substances. Eleven studies showed a clinical improvement after aripiprazole treatment. 8 studies evaluated craving and found a significant reduction after treatment with aripiprazole. No definitive conclusions can be drawn on substance usage and maintenance of abstinence.</p><p><strong>Conclusion: </strong>The present findings suggest aripiprazole may be associated with reducing substance craving and improving depression, psychosis, and schizoaffective disorders in dually diagnosed patients.</p>","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1570159X23666241023115252","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Co-occurrence of substance use disorders is frequent in patients with mental health disorders is a condition known as "dual diagnosis". The use of substances worsens the prognosis and lowers the quality of life of psychiatric patients. It also increases the risk of hospitalization and suicide rate.

Objectives: To assess the effects of aripiprazole therapy on substance use and other psychiatric outcomes in dually diagnosed patients.

Methods: We performed a systematic review conducted on 3 databases PUBMED, SCOPUS, and Web of Science, selecting original studies and analyzing the impact of aripiprazole therapy on dually diagnosed patients. Six hundred and fifty-five articles were founded and, after removing duplicates (n = 274) and applying the exclusion criteria, 12 articles were included in our systematic review.

Results: 12 studies were included, among which 6 were Randomized Controlled Trials. The Most frequent psychiatric diagnosis were schizoaffective disorders, schizophrenia, and bipolar disorders. Alcohol and cocaine use disorders were the most used substances. Eleven studies showed a clinical improvement after aripiprazole treatment. 8 studies evaluated craving and found a significant reduction after treatment with aripiprazole. No definitive conclusions can be drawn on substance usage and maintenance of abstinence.

Conclusion: The present findings suggest aripiprazole may be associated with reducing substance craving and improving depression, psychosis, and schizoaffective disorders in dually diagnosed patients.

口服和长效注射阿立哌唑治疗严重精神疾病和药物使用障碍合并症:最新系统综述。
背景:精神疾病患者经常同时患有药物使用障碍,这种情况被称为 "双重诊断"。使用药物会恶化精神病患者的预后,降低他们的生活质量。目标:评估阿立哌嗪对精神疾病患者的影响:评估阿立哌唑治疗对双重诊断患者药物使用和其他精神疾病结果的影响:我们在 PUBMED、SCOPUS 和 Web of Science 3 个数据库中进行了系统性综述,选择了原创性研究并分析了阿立哌唑疗法对双重诊断患者的影响。共找到 655 篇文章,在去除重复文章(n = 274)并应用排除标准后,有 12 篇文章被纳入我们的系统综述:结果:共纳入 12 项研究,其中 6 项为随机对照试验。最常见的精神病诊断为精神分裂情感障碍、精神分裂症和双相情感障碍。使用最多的药物是酒精和可卡因。11项研究显示,阿立哌唑治疗后临床症状有所改善。8项研究对渴求进行了评估,发现阿立哌唑治疗后渴求明显减少。关于药物使用和戒断维持情况,目前还不能得出明确结论:本研究结果表明,阿立哌唑可能与减少双重诊断患者的药物渴求和改善抑郁、精神病和精神分裂症相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Neuropharmacology
Current Neuropharmacology 医学-神经科学
CiteScore
8.70
自引率
1.90%
发文量
369
审稿时长
>12 weeks
期刊介绍: Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience. The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信